Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey

Sequential endocrine therapy (ET) is recommended for postmenopausal women with hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2−) metastatic breast cancer (mBC) and without visceral symptoms. Chemotherapy (CT) can be considered after sequential ETs, but is asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Peggy L., Hao, Yanni, Xie, Jipan, Li, Nanxin, Zhong, Yichen, Zhou, Zhou, Signorovitch, James E., Wu, Eric Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735772/
https://www.ncbi.nlm.nih.gov/pubmed/26686532
http://dx.doi.org/10.1002/cam4.580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735772/
https://www.ncbi.nlm.nih.gov/pubmed/26686532
http://dx.doi.org/10.1002/cam4.580

Ejemplares similares